Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Clonal evolution and molecular stratification of urothelial carcinoma in situ of the urinary bladder

Funder: German Research Foundation

Funding period
0
Funding amount
Abstract
Bladder cancer is a heterogeneous disease with divergent clinical and oncological courses. Urothelial carcinoma in situ (CIS) is the aggressive pre-invasive intraurothelial lesion, from which the majority of muscle-invasive bladder carcinomas with poor prognosis arises. So far, neither the molecular evolution of CIS is sufficiently understood, nor is it possible to predict which CIS patients will have stable disease that can be treated with conservative intravesical instillation therapy, and which patient group will progress and might benefit from undergoing early cystectomy. Furthermore, first-line therapy, i.e. intravesical instillation of bacillus Calmette-Guérin (BCG), fails in more than 50 % of cases due to toxicity or treatment resistance, and second-line therapy radical cystectomy results in possible overtreatment and causes drastic lifestyle consequences. Therefore, in this proposal we aim to decipher the genetic landscape of urothelial CIS by performing a multiregional whole exome sequencing approach, initially on cryopreserved, completely embedded cystectomy specimens containing CIS. We will use bioinformatics to analyse clonal heterogeneity and evolution of CIS in order to understand the basic disease development and its dynamics, and to deduce prognostically relevant information for therapeutic stratification as well as to identify genetic events which hold promise for effective targeted therapy. Potentially druggable CIS alterations will be assessed functionally in in vitro models for their putative predictive and therapeutic impact. Based on the assumption that a more diverse tumour is able to adapt more efficiently to changing environmental conditions resulting in faster tumour growth and progression, we aim to determine the suitability of inter-patient within-CIS genetic diversity measures as a robust criterion for independent prognostic stratification (intravesical therapy versus radical cystectomy). Prospectively (in subsequent projects), we aim to validate the basic results from this project for CIS risk stratification in longitudinal biopsy cohorts, that we are currently establishing.
Similar projects All >
Sorted by: Start Date
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Jonathan David Spicer, Ciriaco A. Piccirillo

USD 138,878
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Effect of APOBEC3 on Bladder Cancer Biology and Response to Immunotherapy

National Cancer Institute to ANDREW TRUONG

USD 45,016
2020 - 2023
Project list item
Analysis of the antineoplastic action of Class I HDAC inhibitors to define new combination therapies for urothelial carcinoma

German Research Foundation to Günter Niegisch, Michèle Janine Hoffmann

 
2020 -

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science